• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Skip to investors navigation
Insmed

Insmed

Powered by Purpose

LinkedIn Twitter Contact Us Job Opportunities

  • Culture
    • Our Culture
      • Mission & Vision
      • Careers
      • Responsibility
        • Inclusion at Insmed
        • Grants & Funding
        • Global Healthcare Compliance

    Our Global Company

    Find available career opportunities in the U.S., Japan, or Europe.

    Find Jobs

  • Patients
    • Our Patients
      • Disease Areas
      • Resources
      • Patient Access

    Current Clinical Trials

    You may be eligible for one of our clinical trials.

    See if you may qualify

  • Science
    • Our Science
      • ARIKAYCE®
      • Our Research
      • Pipeline
      • Clinical Trials
      • Investigator-Initiated Research

    Our Research Team

    Working together to develop new medicines and technologies that have the potential to transform patients’ lives.

    Learn More

  • About
    • About Insmed
    • Management Team
    • Board of Directors
    • Partnerships
  • Investors
    • Investors
    • Events & Presentations
    • Stock Information
    • News Releases
    • SEC Filings
    • Annual Reports
    • Analyst Coverage
    • Corporate Governance
    • Email Alerts
    • Investor FAQs
Home / Investors/ News Releases

News Releases

Month Year
Su Mo Tu We Th Fr Sa
Month Year
Su Mo Tu We Th Fr Sa
Email Alerts
Advanced Search
  
Asset Types
           
 Basic Search
  • Sep 1, 2021
    Insmed To Participate in Five September Conferences
  • Aug 6, 2021
    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • Aug 5, 2021
    Insmed Reports Second Quarter 2021 Financial Results and Provides Business Update
    --ARIKAYCE® (amikacin liposome inhalation suspension) Now Launched in Japan; Available in Three Major Territories--
  • Jul 27, 2021
    Insmed to Host Second Quarter 2021 Financial Results Conference Call on Thursday, August 5, 2021
  • Jul 8, 2021
    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • Jun 4, 2021
    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • May 25, 2021
    Insmed To Present at Two June Conferences
  • May 19, 2021
    Insmed Presents Broad Range of Data Across Its Three Programs at the American Thoracic Society 2021 International Conference
    -Retrospective analysis of patients with COPD and NTM lung disease demonstrates statistically significantly higher mortality compared to patients with COPD without NTM lung disease-
  • May 13, 2021
    Insmed Announces Closing of Public Offerings of Common Stock and Convertible Senior Notes and Full Exercise of Underwriters' Options to Purchase Additional Shares and Notes
  • May 11, 2021
    Insmed Announces Pricing of Concurrent Public Offerings of Common Stock and Convertible Senior Notes due 2028
  • May 10, 2021
    Insmed Announces Proposed Concurrent Public Offerings of Common Stock and Convertible Senior Notes due 2028
  • May 7, 2021
    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • May 6, 2021
    Insmed Reports First Quarter 2021 Financial Results and Provides Business Update
    --ARIKAYCE® (amikacin liposome inhalation suspension) Approved in Japan for Patients with NTM Lung Disease Caused by MAC Who Did Not Sufficiently Respond to Prior Treatment with a Multidrug Regimen--
  • Apr 22, 2021
    Insmed to Host First Quarter 2021 Financial Results Conference Call on Thursday, May 6, 2021
  • Apr 7, 2021
    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • Mar 23, 2021
    ARIKAYCE® (amikacin liposome inhalation suspension) Approved by Japan's Ministry of Health, Labour and Welfare for the Treatment of Patients with NTM Lung Disease Caused by MAC Who Did Not Sufficiently Respond to Prior Treatment with MDR
    -- First and Only Therapy Approved in Japan, Europe, and United States for This Difficult-To-Treat Condition --
  • Mar 5, 2021
    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • Feb 25, 2021
    Insmed Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
    --ARIKAYCE EU Launch Progresses, with Product Now Available and Reimbursed in Germany and the Netherlands--
  • Feb 24, 2021
    Insmed to Present at Two March Conferences
  • Feb 19, 2021
    Insmed Announces Topline Results from Phase 1 Study of Treprostinil Palmitil Inhalation Powder (TPIP)
    --TPIP Generally Safe and Well Tolerated in Healthy Volunteers--
  • Feb 16, 2021
    Insmed to Host Conference Call to Discuss Topline Data from Treprostinil Palmitil Inhalation Powder Phase 1 Study
    --Call Scheduled for Friday, February 19, 2021, at 8:30 a.m. ET--
  • Feb 12, 2021
    Insmed to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call on Thursday, February 25, 2021
  • Feb 5, 2021
    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • Jan 5, 2021
    Insmed to Present at the 39th Annual J.P. Morgan Healthcare Conference
  • Jan 4, 2021
    Insmed Initiates Frontline Clinical Trial Program for ARIKAYCE® (amikacin liposome inhalation suspension) in Patients with MAC Lung Disease
    --First Patient Dosed in Post-Marketing Program Intended to Support Full FDA Approval of ARIKAYCE and sNDA in Newly Diagnosed Patients--
  • Dec 4, 2020
    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • Dec 2, 2020
    Insmed Announces Initiation of Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis
    --First Patient Dosed in Global, Registrational Study of First-in-Class Treatment Candidate--
  • Nov 24, 2020
    Insmed to Present at the Evercore ISI 3rd Annual HealthCONx Conference
  • Nov 13, 2020
    Insmed Receives Priority Medicines (PRIME) Designation from European Medicines Agency (EMA) for Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFBE)
  • Nov 6, 2020
    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • Nov 2, 2020
    Insmed to Present at Two November Conferences
  • Oct 29, 2020
    Insmed Reports Third Quarter 2020 Financial Results and Provides Business Update
    --ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $43.6 Million for Third Quarter 2020--
  • Oct 28, 2020
    European Commission Grants Marketing Authorization for ARIKAYCE® Liposomal 590 mg Nebuliser Dispersion for the Treatment of NTM Lung Infections Caused by MAC in Adult Non-CF Patients with Limited Treatment Options
    -- ARIKAYCE is the First and Only Therapy Approved in Both the European Union and United States for This Difficult-To-Treat Condition --
  • Oct 20, 2020
    Insmed to Host Third Quarter 2020 Financial Results Conference Call on Thursday, October 29, 2020
  • Oct 2, 2020
    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • Sep 30, 2020
    Insmed Highlights Progress Across Portfolio and Outlines Growth Strategy at R&D Day
    - Initiated Phase 1 study of treprostinil palmitil inhalation powder (TPIP); Phase 2a study in pulmonary arterial hypertension planned for 2021 -
  • Sep 16, 2020
    Insmed to Host R&D Day on September 30, 2020
  • Sep 9, 2020
    Insmed to Present at Three September Conferences
  • Sep 7, 2020
    New England Journal of Medicine Publishes Positive Results from Phase 2 WILLOW Study of Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis
    --New Data from WILLOW Study also Presented During Late-Breaking Session at European Respiratory Society International Congress--
  • Sep 4, 2020
    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • Aug 7, 2020
    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • Aug 6, 2020
    Insmed Reports Second Quarter 2020 Financial Results and Provides Business Update
    --ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $42.5 Million for Second Quarter 2020--
  • Jul 27, 2020
    Insmed to Host Second Quarter 2020 Financial Results Conference Call on Thursday, August 6, 2020
  • Jul 24, 2020
    Insmed Receives Positive CHMP Opinion for ARIKAYCE Liposomal 590 mg Nebuliser Dispersion for the Treatment of NTM Lung Infections Caused by MAC in Non-CF Patients with Limited Treatment Options
    - If Approved, ARIKAYCE Will Be First and Only Therapy in the European Union for This Difficult-to-Treat Condition -
  • Jul 7, 2020
    New NTM Treatment Guidelines Recommend Insmed's ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of Patients with Refractory MAC Lung Disease
    --First update to treatment guidelines in more than a decade, marking important milestone in patient care--
  • Jul 6, 2020
    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • Jun 24, 2020
    Positive Results from Phase 2 WILLOW Study of Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis Presented at ATS Virtual Clinical Trials Session
    --Brensocatib Shown to Reduce Time to First Pulmonary Exacerbation and Reduce Rate of Exacerbations Versus Placebo--
  • Jun 8, 2020
    Insmed Receives FDA Breakthrough Therapy Designation for Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFBE)
    --Full Results from Phase 2 WILLOW Study of Brensocatib in NCFBE to be Presented at Virtual ATS Session on June 24, 2020--
  • Jun 5, 2020
    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • May 26, 2020
    Insmed to Present at Two June Conferences
Show 5102550100 per page
  • «
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 13
  • »
Stay In The Loop

Want to stay up to date on our news, events, and filings? Set up your
email alerts.

Sign Up

View the latest Insmed Investor Presentation

Download

Primary Sidebar

Investor Menu

  • Investors
  • Events & Presentations
  • Stock Information
  • News Releases
  • SEC Filings
  • Annual Reports
  • Analyst Coverage
  • Corporate Governance
  • Email Alerts
  • Investor FAQs

Investor Menu

Footer

Insmed
LinkedIn Twitter

Contact Us

Job Opportunities

  • Our Culture
    • Mission & Vision
    • Careers
    • Responsibility
      • Inclusion at Insmed
      • Grants & Funding
      • Global Healthcare Compliance
  • Our Patients
    • Disease Areas
    • Resources
    • Patient Access
  • Our Science
    • ARIKAYCE®
    • Our Research
    • Pipeline
    • Clinical Trials
    • Investigator-Initiated Research
  • About
    • Management Team
    • Board of Directors
    • Partnerships
  • Investors
  • Events & Presentations
  • Stock Information
  • News Releases
  • SEC Filings
  • Annual Reports
  • Analyst Coverage
  • Corporate Governance
  • Email Alerts
  • Investor FAQs

© 2023 Insmed Incorporated. All Rights Reserved. Terms of Use Privacy Policy

Culture
Patients
Science
logo
  • Culture
    • Mission & Vision
    • Careers
    • Responsibility
      • Inclusion at Insmed
      • Grants & Funding
      • Global Healthcare Compliance
  • Patients
    • Disease Areas
    • Resources
    • Patient Access
  • Science
    • ARIKAYCE®
    • Our Research
    • Pipeline
    • Clinical Trials
    • Investigator-Initiated Research
  • About
    • Management Team
    • Board of Directors
    • Partnerships
  • Investors
    • Investors
    • Events & Presentations
    • Stock Information
    • News Releases
    • SEC Filings
    • Annual Reports
    • Analyst Coverage
    • Corporate Governance
    • Email Alerts
    • Investor FAQs

LinkedIn Twitter

Contact Us Job Opportunities

© 2023 Insmed Incorporated.
All Rights Reserved.

Terms of Use Privacy Policy